Grail, Inc. (GRAL)
GRAIL, Inc. (GRAL) Q4 2025 Earnings Call Transcript
GRAIL, Inc. (GRAL) Q4 2025 Earnings Call Transcript
GRAIL Submits FDA PMA for Galleri Multi-Cancer Early Detection Test
GRAL submits final FDA PMA module for the Galleri MCED test, reaching a milestone in broader cancer screening and potential public health impacts.
GRAIL, Inc. (GRAL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
GRAIL, Inc. (GRAL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Small-Cap Standouts: These 3 Stocks Rose Over 300% in 2025
In 2025, small-cap stocks underperformed. The Russell 2000 Index tracks the performance of 2,000 U.S. small-cap stocks, delivering a total return of around 13% in 2025.
An Auto Holy Grail: Motors That Don't Rely on Chinese Rare Earths
Weary of being captive to geopolitics, car companies are looking for ways to replace powerful rare-earth magnets in electric motors.
Why GRAIL Stock Could Be Biotech's Next Big Breakout
Retail investors are understandably on edge after several sessions of market volatility. But bestselling author and Oxford Club strategist Alexander Green, in his new book The American Dream, says we're still in one of the best times in history to build wealth—especially if you think long-term and stay grounded in time-tested principles.
Grail Q3 Earnings: Massive Stock Gains, Mediocre Performance - I'm Still Not Sold
Grail (GRAL) reported Q3 revenues of $36.2m, up 26% YoY, but continues to post significant losses and faces commercial challenges. Galleri test's PATHFINDER 2 study showed promising early cancer detection, yet questions remain about detection rates, pricing, and broad adoption, in my view. GRAL's stock has surged 185% since my last Hold call, despite lack of FDA approval and ongoing uncertainty around reimbursement, market size, and future profitability.
GRAIL, Inc. (GRAL) Q3 2025 Earnings Call Transcript
GRAIL, Inc. ( GRAL ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Robert Ragusa - CEO & Director Joshua Ofman - President Harpal Kumar - Chief Scientific Officer & President International Aaron Freidin - Chief Financial Officer Andrew Partridge - Chief Commercial Officer Conference Call Participants Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Douglas Schenkel - Wolfe Research, LLC Bradley Bowers - Mizuho Securities USA LLC, Research Division Presentation Operator Good day, ladies and gentlemen, and welcome to the GRAIL Third Quarter 2025 Earnings Call. [Operator Instructions] Please be advised that this conference call is being recorded.
GRAIL: Buy Τhe Test That Could Redefine Cancer Screening
GRAIL moves from scientific vision to proven clinical reality, as PATHFINDER 2 confirms that multi-cancer early detection works effectively at scale. Physician and patient adoption is accelerating, supported by partnerships with Quest Diagnostics, telemedicine providers, and employer health programs. The company's financial position is reinforced by $435 million in new funding, including strategic backing from Samsung for expansion into Asian markets.
GRAIL, Inc. (GRAL) Discusses PATHFINDER 2 Study Results and Clinical Program in Multi-Cancer Early Detection Transcript
GRAIL, Inc. (NASDAQ:GRAL ) Discusses PATHFINDER 2 Study Results and Clinical Program in Multi-Cancer Early Detection October 20, 2025 8:00 AM EDT Company Participants Robert Ragusa - CEO & Director Joshua Ofman - President Harpal Kumar - President of International Business & BioPharma Aaron Freidin - Chief Financial Officer Conference Call Participants Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Yuko Oku - Morgan Stanley, Research Division Douglas Schenkel - Wolfe Research, LLC Presentation Operator Good day, ladies and gentlemen, and welcome to today's GRAIL analyst call. [Operator Instructions] Please be advised that this conference call is being recorded.
Grail: A Speculative Buy
Grail, Inc. represents a speculative long-term investment opportunity, conditional on the FDA's approval of its Galleri multi-cancer early detection blood test and its widespread adoption among the general population. Assuming FDA approval, GRAL could reach $100–$250 per share, based on reasonable assumptions regarding its total addressable market and the prevailing competitive landscape. Galleri's robust revenue growth as a predominantly self-paid test over the past three years provides a reasonable margin of safety against the risk of FDA non-approval.
GRAIL, Inc. (GRAL) Q2 2025 Earnings Call Transcript
GRAIL, Inc. (NASDAQ:GRAL ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Aaron Freidin - Chief Financial Officer Andrew John Partridge - Chief Commercial Officer Harpal S. Kumar - President of International Business & BioPharma Joshua J.
